Home ivps4 2017-06-16T21:39:52+00:00

News Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Investor Alerts

Sep 18, 2020

Achieve Announces Presentation of Investigator-Led RAUORA Trial Data Demonstrating Significantly Fewer Side Effects with Higher Quit Rates for Cytisinicline (cytisine) Compared to Chantix® (varenicline) in First Head-to-Head Comparative Study

Subjects in the Cytisinicline Arm Were 55% More Likely to Quit Smoking at 6 Months Compared to Subjects Who Received Varenicline
Sep 18, 2020

Achieve Life Sciences Announces Results from Evaluation of Cytisinicline (cytisine) versus Chantix® (varenicline) in 5-HT3 Receptor Binding Assay Study

Provides Mechanistic Rationale for the Clinical Findings that Cytisinicline (Cytisine) Treatment is Associated with Lower Rates of Nausea and Vomiting compared to Chantix
Sep 10, 2020

Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 20th Annual Society for Research on Nicotine & Tobacco Europe (SRNT-E) Virtual Conference
Sep 3, 2020

Achieve Life Sciences to Present at Upcoming Investor Conferences
Aug 6, 2020

Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program
Aug 4, 2020

Achieve Life Sciences Announces Pricing of $6.5 Million Public Offering
Aug 3, 2020

Achieve Life Sciences Announces Proposed Public Offering
Jul 31, 2020

Achieve Announces Patent Granted in the U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications
Jul 28, 2020

Achieve Life Sciences to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020
Jun 29, 2020

Achieve Life Sciences Announces Pricing of $6 Million Registered Direct Offering

Show per page

Stock Info